Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

596
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
596
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

2.8K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
2.8K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.6K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.6K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.7K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

900
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
900
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.2K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of advanced therapies for intermediate- to high-risk pulmonary embolism with improved right ventricular function on outpatient follow-up among survivors.

Frontiers in cardiovascular medicine·2026
Same author

Pathway for the Diagnosis and Management of Pericardial Disease: Contemporary Perspective.

Critical pathways in cardiology·2026
Same author

Neutrophil-to-lymphocyte ratio in patients with low-flow aortic stenosis undergoing transcatheter aortic valve implantation.

Journal of cardiology·2026
Same author

Continuous-wave Doppler interrogation in valvular heart disease: pearls and pitfalls.

European heart journal. Imaging methods and practice·2026
Same author

Flow Normalization and Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement Across Low-Flow Aortic Stenosis Phenotypes.

The American journal of cardiology·2026
Same author

A Simplified, Tier-Based Method for Clinical Evaluation of Diastolic Function.

European heart journal. Cardiovascular Imaging·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 28, 2026

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.5K

Misconceptions and Facts About Beta-Blockers.

Edgar Argulian1, Sripal Bangalore2, Franz H Messerli3

  • 1Division of Cardiology, Mt Sinai St. Luke's Hospital, New York.

The American Journal of Medicine
|March 1, 2019
PubMed
Summary
This summary is machine-generated.

Beta-blockers are widely used but often overprescribed for hypertension. While beneficial in heart failure, evidence for their cardioprotective role in uncomplicated hypertension is limited, necessitating updated clinical practice guidelines.

Keywords:
Beta-blockersCardioprotectionCoronary artery disease

More Related Videos

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

14.0K
In situ Quantification of Pancreatic Beta-cell Mass in Mice
09:50

In situ Quantification of Pancreatic Beta-cell Mass in Mice

Published on: June 7, 2010

12.6K

Related Experiment Videos

Last Updated: Jan 28, 2026

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.5K
Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

14.0K
In situ Quantification of Pancreatic Beta-cell Mass in Mice
09:50

In situ Quantification of Pancreatic Beta-cell Mass in Mice

Published on: June 7, 2010

12.6K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are frequently prescribed medications.
  • Traditionally, they have been regarded as cardioprotective agents.

Purpose of the Study:

  • To evaluate the evidence supporting the cardioprotective role of beta-blockers.
  • To clarify the appropriate use of beta-blockers in clinical practice, particularly in hypertension and heart failure.

Main Methods:

  • Review of clinical evidence and guidelines regarding beta-blocker efficacy.
  • Comparative analysis of beta-blocker outcomes versus other antihypertensive agents.

Main Results:

  • Beta-blockers demonstrate efficacy in heart failure with reduced ejection fraction by counteracting neurohumoral activation.
  • Outcomes in uncomplicated hypertension are suboptimal compared to first-line agents, suggesting overutilization.

Conclusions:

  • The clinical application of beta-blockers may exceed the supporting evidence, especially in uncomplicated hypertension.
  • Healthcare providers need awareness of misconceptions to ensure appropriate beta-blocker prescription.